Q32 Bio Inc QTTB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QTTB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $28.02
- Day Range
- $27.99–29.20
- 52-Week Range
- $8.24–30.92
- Bid/Ask
- $15.00 / $35.00
- Market Cap
- $346.43 Mil
- Volume/Avg
- 27,388 / 33,177
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.q32bio.com
Valuation
|
Metric
|
QTTB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
QTTB
|
|---|---|
Quick Ratio | 0.51 |
Current Ratio | 0.54 |
Interest Coverage | — |
Quick Ratio
QTTB
Profitability
|
Metric
|
QTTB
|
|---|---|
Return on Assets (Normalized) | −52.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
QTTB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qvlpyrynv | Wfn | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nstfgxkzb | Vyylrz | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sndjsvsn | Lspjdx | $98.3 Bil | |
MRNA
| Moderna Inc | Sqwmqsfxy | Dmnn | $42.7 Bil | |
ARGX
| argenx SE ADR | Jctzgwxm | Clbw | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Pkflshg | Qwlcx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jhmswts | Ffnyyb | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ktssjtg | Nqlfzn | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tcvckvpyl | Pwqhflj | $12.7 Bil | |
INCY
| Incyte Corp | Lqyytvhll | Vsjmcc | $11.8 Bil |